Originally published by our sister publication Specialty Pharmacy Continuum
By Myles Starr
This summer, the FDA proposed removing the requirement that biosimilar drug manufacturers submit clinical switching studies to demonstrate interchangeability between their product and a brand-name reference drug. This move, which aims to boost competition between manufacturers and bring down costs for patients, drew support from the Federal Trade Commission. 
Under new proposed guidelines, in lieu of a